Antiretroviral pre‐exposure prophylaxis implementation in the United States: a work in progress

• DOI: 10.7448/ias.18.4.19980
• Publication Date: 2015-07-20T09:32:43Z
• Authors: Kenneth H Mayer; Sybil Hosek; Stephanie Cohen; Albert Liu; Jim Pickett; Mitchell Warren; Douglas Krakower; Robert Grant
• Keywords: Pre-exposure prophylaxis; Underinsured; Emtricitabine; Best practice

After the initial approval of use tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) by US Food and Drug Administration in 2012 for anti-HIV pre-exposure prophylaxis (PrEP), uptake was initially limited, but more recent community surveys expert opinion suggest wider acceptance some key populations.Demonstration projects are underway to determine best practices United States identify at-risk individuals primary care sexually transmitted disease clinics who could benefit from PrEP. Studies PrEP combination with behavioural interventions being evaluated. evaluate HIV-uninfected women HIV-discordant couples interested safe conception also getting underway. The optimal deployment as part a comprehensive national HIV/AIDS strategy has been limited lack knowledge among people medical providers indicating that they do not feel sufficiently knowledgeable comfortable prescribing how assist busy clinicians which their patients Although most federal health insurance programmes will cover costs associated PrEP, underinsured states have enacted reform face additional challenges paying medication appropriate clinical monitoring.PrEP implementation is work progress, increasing awareness populations.